RPL17 and gastric cancer: Relatlimab received FDA approval in 2022 for use in fixed-dose combination with the PD - 1 inhibitor nivolumab for the treatment of unresectable or metastatic melanoma. In gastric cancer, relatlimab is under clinical investigation primarily in combination with other ICIs; however, trial results are not yet available